Lupin Invests $250 Million in New Respiratory Drug Manufacturing Plant in Florida

Generic pharmaceutical giant Lupin is set to construct a cutting-edge manufacturing facility in Coral Springs, Florida, with a $250 million investment focused on producing 25 essential respiratory medicines. Although details on the plant’s size and job creation have not been disclosed, the project represents a significant expansion of the company’s U.S. footprint.

Chief Technical Operations Officer Christoph Funke described the development as “a core component of our growth strategy,” noting that it builds on Lupin’s existing local presence and will partner with key stakeholders to enhance supply chain efficiency.

The plant is poised to strengthen Lupin’s position in the respiratory drug market, ensuring greater access to affordable treatments for patients worldwide.